GlaxoSmithKline (GSK) Reports Q1 EPS of 167p; Will Retain Stake in ViiV Healthcare

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to GlaxoSmithKline (GSK) Reports Q1 EPS of 167p; Will Retain Stake in ViiV Healthcare

ViiV Healthcare Commences Dolutegravir, Rilpivirine Phase 3 in HIV (GSK) (PFE)

May 6, 2015 7:03 AM EDT

ViiV Healthcare announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. The Phase III programme comprises two replicate studies evaluating 48 week viral suppression with a two drug regimen combining an integrase inhibitor (dolutegravir) and a non-nucleoside reverse transcriptase inhibitor (rilpivirine) in patients with HIV who have already achieved viral suppression with a three drug regimen.

"As HIV care becomes an increasingly long term consideration, patients and clinicians are seeking... More